Follow-up Testing After Kidney Cancer Treatment

Core Surveillance Components

The American Urological Association recommends that patients with treated malignant renal masses receive medical history and physical examination at intervals determined by risk stratification 1
The National Comprehensive Cancer Network recommends laboratory monitoring including serum creatinine, estimated glomerular filtration rate, and urinalysis at each visit 1, 2
Additional labs (complete blood count, lactate dehydrogenase, liver function tests, alkaline phosphatase, calcium) should only be performed at clinician discretion or when advanced disease is suspected 1, 3

For patients with Stage I (pT1a and pT1b) kidney cancer after nephrectomy, the National Comprehensive Cancer Network recommends clinical visits and labs every 6 months for 2 years, then annually up to 5 years 4, 5
The National Comprehensive Cancer Network recommends baseline abdominal imaging (CT, MRI, or ultrasound) within 3-12 months after surgery for patients with Stage I kidney cancer 4, 5
For patients with Stage II-III kidney cancer after radical nephrectomy, the National Comprehensive Cancer Network recommends clinical visits every 3-6 months for 3 years, then annually up to 5 years 5, 6
The National Comprehensive Cancer Network recommends imaging (chest CT and abdominal CT/MRI) every 3-6 months for at least 3 years, then annually up to 5 years for patients with Stage II-III kidney cancer 5, 6
CT is preferred over ultrasound for high-risk patients due to superior sensitivity for recurrence detection 6

The American Urological Association recommends that bone scan should be performed ONLY when one or more of the following is present: bone pain, elevated alkaline phosphatase, or radiographic findings suggestive of bony neoplasm 1, 2, 3
The American Urological Association recommends that brain/spine imaging (MRI or CT) should be obtained ONLY with acute neurological signs or symptoms 1, 2, 3
The American Urological Association recommends that PET scan should NOT be obtained routinely but may be considered selectively in specific circumstances 1, 3

The National Comprehensive Cancer Network recommends that follow-up extends for at least 5 years, with continuation beyond 5 years at physician discretion, as some relapses occur after 5 years 4, 8
If microscopic margins are positive, consider the risk category at least one level higher and increase surveillance intensity 1, 3
Patients with pathologically-proven benign masses require only occasional clinical evaluation and laboratory testing for treatment sequelae; most do not need routine periodic imaging 1, 2
Consider referral to nephrology to prevent further renal function deterioration, which affects bone health, metabolic health, and cardiovascular risk 1, 3